New ETF Book by Larry Connors - Click here to read more
--Record $49 million debt reduction in the third quarter
American Medical Systems Holdings, Inc. (NASDAQ: AMMD | Quote | Chart | News | PowerRating) reported revenue of $123.2 million for the third quarter of 2009, a 4.9 percent increase from revenue of $117.5 million in the comparable quarter of 2008. The strengthening of the U.S. dollar had a negative impact on revenue of $2.1 million in the third quarter compared to the prior year. Excluding the impact of foreign currency fluctuations, third quarter revenue grew 6.7 percent over the same period last year. On a GAAP basis, the Company reported 2009 third quarter net income of $28.6 million, or $0.38 per share, compared to net income in the same period last year of $3.5 million, or $0.05 per share. Included in the third quarter 2009 net income was a $17.4 million pre-tax gain on the sale of the Ovion technology as well as a $5.6 million pre-tax gain on the exchange of the majority of the Company's 3.25% Convertible Senior Subordinated Notes due 2036, completed during the quarter. Third quarter 2008 net income was reduced for a $7.5 million pre-tax in-process research and development (IPRD) charge on a milestone payment related to a prior acquisition.
The Company also reported very strong non-GAAP adjusted EPS performance in the third quarter of 2009 of $0.27 per share compared to $0.18 per share in the comparable period last year. This exceeds the Company's non-GAAP adjusted EPS guidance of $0.17 to $0.21 per share for the third quarter. Non-GAAP adjusted EPS excludes the impact of the amortization of intangible assets and amortization of financing costs, both significant non-cash items affecting comparability to other companies. The non-GAAP adjusted net income for the third quarter of 2009 also excludes the gain on sale of the Ovion technology and the gain on exchange of the majority of its convertible notes during the quarter. Non-GAAP adjusted EPS for the third quarter of 2008 excludes the IPRD charge on a milestone payment related to a prior acquisition. A reconciliation of reported net income to non-GAAP adjusted net income is provided in the attached schedules.
Men's Health led the third quarter revenue growth, which at $54.7 million was up 6.6 percent on a reported basis compared to the same quarter last year and grew 8.7 percent on a constant currency basis. Erectile restoration revenue growth continued its strong performance, while third quarter male continence revenue growth improved over the muted growth we experienced in the second quarter. Our BPH therapy business was up 3.1 percent on a reported basis and grew 4.9 percent on a constant currency basis to $27.7 million during the quarter, driven by strong sales of laser fibers, particularly in our United States market. The Women's Health business increased 4.0 percent on a reported basis and 5.4 percent on a constant currency basis to $40.9 million in the third quarter. Highlighting the quarter was very strong performance from our pelvic floor repair products, benefiting from the recent launch of our new Elevate(R) anterior product. Third quarter revenue growth rates from our female continence products improved over second quarter growth rates and, as anticipated, sales from uterine health declined this quarter.
"We are very pleased with the strong financial performance in the third quarter of 2009, demonstrated by accelerated growth rates across all three business units. Particularly notable, we returned to a growth position in our BPH business, despite continued softness in capital sales," stated Tony Bihl, Chief Executive Officer. "In addition, we completed two very strategic transactions in the quarter: the sale of the Ovion technology and the $250 million exchange of our convertible notes. Operationally, we continued with our disciplined approach to spending and working capital management, which combined with the cash we received from the sale of the Ovion technology allowed us to make cash payments at a record quarterly amount of $49 million on our debt. We delivered revenue and earnings exceeding the high end of guidance and as a result, have increased our expectations for full year 2009 revenue and earnings performance."
Outlook
The Company estimates fourth quarter revenue in the range of $136 to $142 million, resulting in full year 2009 revenue guidance of $509 to $515 million; an increase from previous 2009 revenue guidance of $495 to $510 million. This guidance assumes foreign currency exchange rates remain constant with current rates.
In May 2008, the Financial Accounting Standards Board (FASB) issued new guidance related to accounting for convertible debt instruments, which the Company adopted in the first quarter 2009 (and applied retrospectively to prior periods). This new guidance changed the balance sheet classification of a component of the Company's convertible notes between equity and debt, and resulted in additional non-cash interest charges being reflected in the statement of operations. The Company estimates that the adoption of this new accounting guidance will reduce net income for fiscal year 2009 by approximately $0.11 per share.
Given the significant impact of the amortization of financing costs resulting from the implementation of the new FASB guidance in 2009, combined with the amortization of intangible assets, the Company has two significant non-cash charges in GAAP earnings that create inconsistencies in comparisons to many other companies. Accordingly the Company now guides to non-GAAP adjusted earnings per share, which the Company defines as GAAP earnings per share excluding the impact of amortization of intangible assets and amortization of financing costs. This guidance also excludes the impact of any unusual non-recurring items that could occur in 2009, such as the gain on early debt extinguishment, the gain on sale of non-strategic assets, or IPRD charges on milestone payments related to prior acquisitions.
Reflecting the strong earnings performance experienced in the first three quarters, the Company estimates fourth quarter 2009 non-GAAP adjusted earnings per share will be in the range of $0.29 to $0.33 and full year 2009 non-GAAP adjusted earnings per share in the range of $1.10 to $1.14. This is an increase from previous guidance for the full year 2009 in the range of $1.00 to $1.10. This guidance excludes the impact of amortization of intangible assets which is approximately $0.03 and $0.11 for the fourth quarter and full year 2009, respectively, and amortization of financing costs which is approximately $0.04 and $0.14 for the fourth quarter and full year 2009, respectively. Guidance for both periods excludes the impact of any unusual non-recurring items that could occur, such as gain or loss on early debt extinguishments, sale of non-strategic assets or IPRD charges on milestone payments related to prior acquisitions.
Use of Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), management provides non-GAAP adjusted net income, non-GAAP adjusted earnings per share and constant currency revenue growth rates because management believes that in order to properly understand the Company's short-term and long-term financial trends and for purposes of comparability to other companies, investors may wish to consider the impact of certain adjustments (such as gain on extinguishment of debt, gain on sale of non-strategic assets, IPRD charges, amortization of intangible assets, amortization of financing costs and related income tax adjustments and the impact of foreign currency translation on reported revenue). These adjustments result from facts and circumstances (such as acquisition and business development activities and other non-recurring items) that vary in frequency and impact on the Company's results of operations, represent significant items, which when excluded provide a useful measure to determine the health of the business and earnings by the business before significant non-cash charges or in the case of foreign currency translation, are highly variable and difficult to predict. Management uses non-GAAP adjusted net income, non-GAAP adjusted earnings per share and constant currency revenue growth rates to forecast and evaluate the operational performance of the Company as well as to compare results of current periods to prior periods on a consistent basis.
A reconciliation of net income from continuing operations and revenue growth rate percentages, the GAAP measures most directly comparable to non-GAAP adjusted earnings per share and constant currency revenue growth rates, respectively, are provided on the attached schedules.
Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. Investors should consider non-GAAP measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.
Earnings Call Information
American Medical Systems will host a conference call on Wednesday, November 4, 2009 at 5:00 p.m. eastern time to discuss its 2009 third quarter results. Those without internet access may join the call from within the U.S. by dialing 888-263-1724; outside the U.S., dial 706-679-3821.
A live web cast of the call will be available through the Company's corporate website at www.AmericanMedicalSystems.com and will be available for replay within three hours after the completion of the call.
About American Medical Systems
American Medical Systems, headquartered in Minnetonka, Minnesota, is a diversified supplier of medical devices and procedures to cure incontinence, erectile dysfunction, benign prostate hyperplasia (BPH), pelvic floor repair and other pelvic disorders in men and women. These disorders can significantly diminish one's quality of life and profoundly affect social relationships. In recent years, the number of people seeking treatment has increased markedly as a result of longer lives, higher-quality-of-life expectations and greater awareness of new treatment alternatives. American Medical Systems' products reduce or eliminate the incapacitating effects of these diseases, often through minimally invasive therapies. The Company's products were used to treat approximately 320,000 patients in 2008.
Forward-Looking Statements
This press release contains forward-looking statements relating to the market opportunities, future products, sales and financial results of American Medical Systems. These statements and other statements contained in this press release that are not purely historical fact are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are based on management's beliefs, certain assumptions and current expectations. These forward-looking statements are subject to risks and uncertainties such as successfully competing against competitors; physician acceptance, endorsement, and use of AMS products; potential product recalls or technological obsolescence; successfully managing debt leverage and related credit facility financial covenants; current worldwide economic conditions and the impact on operations of the disruption in global financial markets; factors impacting the stock market and share price and its impact on the dilution of convertible securities; potential obligations to make significant contingent payments under prior acquisitions; ability of the Company's manufacturing facilities to meet customer demand; reliance on single or sole-sourced suppliers; loss or impairment of a principal manufacturing facility; clinical and regulatory matters; timing and success of new product introductions; patient acceptance of the Company's products and therapies; changes in and adoption of reimbursement rates; adequate protection of the Company's intellectual property rights; product liability claims; currency and other economic risks inherent in selling our products internationally and other risks and uncertainties described in the Company's Annual Report on Form 10-K for the year ended January 3, 2009, and its other SEC filings. Actual results may differ materially from anticipated results. The forward-looking statements contained in this press release are made as of the date hereof, and AMS undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
More information about the Company and its products can be found at its website www.AmericanMedicalSystems.com and in the Company's Annual Report on Form 10-K for 2008 and its other SEC filings.
American Medical Systems Holdings, Inc.
Statements of Operations
(Unaudited)
(In thousands, except per share data)
Three Months Ended Nine Months Ended
October 3, 2009 September 27, 2008 October 3, 2009 September 27, 2008
Net sales $ 123,231 $ 117,468 $ 373,257 $ 367,627
Cost of sales 21,284 24,863 66,234 83,038
Gross profit 101,947 92,605 307,023 284,589
Operating expenses
Marketing and selling 42,489 42,226 128,690 133,608
Research and development 12,434 11,260 38,411 33,926
In-process research and development - 7,500 - 7,500
General and administrative 10,459 9,728 32,898 30,435
Amortization of intangibles 3,358 4,334 10,024 12,981
Total operating expenses 68,740 75,048 210,023 218,450
Operating income 33,207 17,557 97,000 66,139
Other (expense) income
Royalty income 961 745 2,768 3,576
Interest income 17 203 163 555
Interest expense (4,674 ) (6,168 ) (15,050 ) (21,044 )
Amortization of financing costs (4,395 ) (4,935 ) (12,350 ) (13,976 )
Gain on extinguishment of debt 5,563 - 10,125 -
Gain on sale of non-strategic asset 17,446 - 17,446 -
Other (expense) income (341 ) (957 ) 935 973
Total other income (expense) 14,577 (11,112 ) 4,037 (29,916 )
Income before income taxes 47,784 6,445 101,037 36,223
Provision for income taxes 19,163 2,940 38,471 14,813
Net income $ 28,621 $ 3,505 (a) $ 62,566 $ 21,410 (a)
Net income per share
Basic net income $ 0.39 $ 0.05 (a) $ 0.85 $ 0.29 (a)
Diluted net income 0.38 0.05 (a) 0.84 0.29 (a)
Weighted average common shares used in calculation
Basic 74,278 73,095 73,939 72,796
Diluted 74,998 74,209 74,456 73,945
(a) Third quarter 2008 net income and basic and diluted net income per
share were reduced by $2,229 and $0.03 per share, respectively, and
year-to-date 2008 net income and basic and diluted net income per
share were reduced by $6,529 and $0.09 per share, respectively, due
to the impact of retroactively adjusting the historical financial
statements, as required by U.S. GAAP, for the change in accounting
related to the Company's 2036 Convertible Notes.
American Medical Systems Holdings, Inc.
Condensed Balance Sheets
(In thousands)
October 3, 2009 January 3, 2009
(Unaudited) (a)
Assets
Current assets
Cash and short-term investments $ 49,511 $ 42,965
Accounts receivable, net 88,198 93,078
Inventories, net 33,629 38,500
Other current assets 18,469 19,766
Total current assets 189,807 194,309
Property, plant and equipment, net 44,777 48,280
Goodwill and intangibles, net 795,040 799,761
Other long-term assets 6,499 2,147
Total assets $ 1,036,123 $ 1,044,497
Liabilities and stockholders' equity
Current liabilities
Accounts payable $ 7,848 $ 7,830
Accrued liabilities and taxes 60,149 55,480
Total current liabilities 67,997 63,310
Debt and other long term liabilities 452,460 553,705
Total liabilities 520,457 617,015
Stockholders' equity 515,666 427,482
Total liabilities and stockholders' equity $ 1,036,123 $ 1,044,497
(a) Retroactively adjusted as of January 3, 2009, as required by U.S.
GAAP, for the change in accounting related to the Company's
Convertible Notes.
American Medical Systems Holdings, Inc.
Condensed Statements of Cash Flows
(Unaudited)
(In thousands)
Nine Months Ended
October 3, 2009 September 27, 2008
Cash flows from operating activities
Net income $ 62,566 $ 21,410 (a)
Adjustments to reconcile net income to net cash provided
by operating activities:
Depreciation and amortization, including deferred financing costs 29,664 34,487 (a)
In-process research and development - 7,500
Gain on extinguishment of debt (10,125 ) -
Gain on sale of non-strategic assets (17,446 ) -
Stock based compensation 6,649 7,135
Other adjustments, including changes in operating assets and 25,877 8,095
liabilities
Net cash provided by operating activities 97,185 78,627
Cash flows from investing activities
Purchase of property, plant and equipment (3,688 ) (4,139 )
Disposal of business - 4,690
Sale of non-strategic assets, net 18,982 -
Purchase of investments in technology - (7,500 )
Purchase of other intangibles (5,392 ) (1,262 )
Purchase of short term investments, net of redemptions 11,895 (21,660 )
Other cash flows from investing activities (171 ) 560
Net cash provided by (used in) investing activities 21,626 (29,311 )
Cash flows from financing activities
Payments on senior secured credit facility (78,173 ) (79,018 )
Repurchase of convertible senior subordinated notes (21,125 ) -
Debt issuance costs (7,697 ) -
Other cash flows from financing activities 6,902 8,623
Net cash used in financing activities (100,093 ) (70,395 )
Effect of currency exchange rates on cash (614 ) (152 )
Net increase in cash and cash equivalents 18,104 (21,231 )
Cash and cash equivalents at beginning of period 11,642 34,044
Cash and cash equivalents at end of period $ 29,746 $ 12,813
(a) Year-to-date 2008 net income was reduced by $6,529 and
amortization of financing costs was increased by $10,479, due to
the impact of retroactively adjusting the historical financial
statements, as required by U.S. GAAP, for the change in accounting
related to the Company's 2036 Convertible Notes. This change in
accounting has no impact on cash used for interest on the 2036
Convertible Notes.
American Medical Systems Holdings, Inc.
Selected Sales Information and Constant Currency Growth
Reconciliation
(Unaudited)
(In thousands)
Three Months Ended Constant Currency Growth Reconciliation (a)
Percent Growth
Currency at Constant
October 3, 2009 September 27, 2008 Percent Growth Impact Currency
Sales
Men's health $ 54,666 $ 51,303 6.6 % $ (1,090 ) 8.7 %
BPH therapy 27,686 26,862 3.1 % (486 ) 4.9 %
Women's health 40,879 39,303 4.0 % (557 ) 5.4 %
Total $ 123,231 $ 117,468 4.9 % $ (2,133 ) 6.7 %
Geography
United States $ 92,262 $ 84,489 9.2 % $ - 9.2 %
International 30,969 32,979 -6.1 % (2,133 ) 0.4 %
Total $ 123,231 $ 117,468 4.9 % $ (2,133 ) 6.7 %
Percent of total sales
Men's health 44 % 44 %
BPH therapy 23 % 23 %
Women's health 33 % 33 %
Total 100 % 100 %
Geography
United States 75 % 72 %
International 25 % 28 %
Total 100 % 100 %
(a) To calculate the currency impact on revenue growth rates, the
Company compares each period's sales, assuming no fluctuation in
foreign currency exchange rates between periods. The generally
accepted accounting principle (GAAP) measure most comparable to this
non-GAAP measure is growth rate percentages based on GAAP revenue.
American Medical Systems Holdings, Inc.
Selected Sales Information and Constant Currency Growth
Reconciliation
(Unaudited)
(In thousands)
Nine Months Ended Constant Currency Growth Reconciliation (a)
Percent Growth
Currency at Constant
October 3, 2009 September 27, 2008 Percent Growth Impact Currency
Sales
Men's health $ 171,090 $ 160,548 6.6 % $ (5,978 ) 10.3 %
BPH therapy 81,159 86,157 -5.8 % (2,817 ) -2.5 %
Women's health 121,008 120,922 0.1 % (3,276 ) 2.8 %
Total $ 373,257 $ 367,627 1.5 % $ (12,071 ) 4.8 %
Geography
United States $ 271,336 $ 258,700 4.9 % $ - 4.9 %
International 101,921 108,927 -6.4 % (12,071 ) 4.6 %
Total $ 373,257 $ 367,627 1.5 % $ (12,071 ) 4.8 %
Percent of total sales
Men's health 46 % 44 %
BPH therapy 22 % 23 %
Women's health 32 % 33 %
Total 100 % 100 %
Geography
United States 73 % 70 %
International 27 % 30 %
Total 100 % 100 %
(a) To calculate the currency impact on revenue growth rates, the
Company compares each period's sales, assuming no fluctuation in
foreign currency exchange rates between periods. The generally
accepted accounting principle (GAAP) measure most comparable to this
non-GAAP measure is growth rate percentages based on GAAP revenue.
American Medical Systems Holdings, Inc.
Reconciliation of Reported Net Income to Non-GAAP Adjusted Net
Income
(Adjustments are presented on a pre-tax basis)
(Unaudited)
(In thousands, except per share data)
Three Months Ended Nine Months Ended
October 3, 2009 September 27, 2008 October 3, 2009 September 27, 2008
Net income, as reported $ 28,621 $ 3,505 (a) $ 62,566 $ 21,410 (a)
Adjustments to net income:
Amortization of intangibles (b) 3,358 4,334 10,024 12,981
Amortization of financing costs (c) 4,395 4,935 12,350 13,976
In-process research and development charge (d) - 7,500 - 7,500
Gain on extinguishment of debt (e) (5,563 ) - (10,125 ) -
Gain on sale of non-strategic asset (f) (17,446 ) - (17,446 ) -
Tax effect of adjustments to net income (g) 6,615 (6,583 ) 2,976 (13,444 )
Non-GAAP adjusted net income $ 19,980 $ 13,691 $ 60,345 $ 42,423
Net income per share
Basic $ 0.39 $ 0.05 $ 0.85 $ 0.29
Diluted $ 0.38 $ 0.05 $ 0.84 $ 0.29
Non-GAAP adjusted earnings per share
Basic $ 0.27 $ 0.19 $ 0.82 $ 0.58
Diluted $ 0.27 $ 0.18 $ 0.81 $ 0.57
Weighted average common shares used in calculation:
Basic 74,278 73,095 73,939 72,796
Diluted 74,998 74,209 74,456 73,945
(a) Third quarter 2008 net income was reduced by $2,229 and year-to-date
2008 net income was reduced by $6,529 to reflect the impact of
retroactively adjusting the historical financial statements, as
required by GAAP, for the change in accounting related to the
Company's Convertible Notes.
(b) Consists of amortization of intangible assets, primarily developed
and core technology.
(c) Consists of amortization of financing costs on our convertible
senior subordinated notes and senior secured credit facility.
(d) Relates to a milestone payment made in the third quarter of 2008 on
the 2006 acquisition of BioControl Medical, Ltd.
(e) Relates to the $5.6 million gain in the third quarter 2009 on
exchanging $250.0 million of 2036 convertible senior subordinated
notes for a like amount of 2041 convertible senior subordinated
notes and year-to-date 2009 also includes the $4.6 million gain in
the first quarter of 2009 on retiring approximately $27.3 million of
2036 convertible senior subordinated notes.
(f) Relates to the gain on sale of female sterilization and Ovion
technology assets.
(g) Includes the tax effect of each of the above items in each of the
periods.
SOURCE: American Medical Systems
American Medical Systems Mark Heggestad, 952-930-6495 Executive Vice President and Chief Financial Officer Mark.Heggestad@AmericanMedicalSystems.com or Anthony Bihl, 952-930-6334 President and Chief Executive Officer Tony.Bihl@AmericanMedicalSystems.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.